Cagrilintide

01 · What it is

Cagrilintide has a substantial clinical literature and almost none of it measures cagrilintide.

The published record is dominated by CagriSema, a fixed-ratio combination of cagrilintide with semaglutide ^6,13. Network meta-analyses report the combination ^4,14; systematic reviews compare the combination ^9,17; a dedicated meta-analysis is titled Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo and treats them together ⁵. Even the delivery hardware has its own publication — a usability study of the dual-chamber pen built to deliver the two components ³.

The exception is REDEFINE 1, a phase 3a, 68-week trial that randomised adults without diabetes to four arms: the combination, semaglutide alone, cagrilintide alone, and placebo ¹⁹. That four-arm design is the only structure in the located literature capable of separating what the amylin analogue contributes from what the GLP-1 agonist contributes. The record examined here is a secondary, post-hoc analysis of that trial.

What it is, and it is not a GLP-1 drug. Cagrilintide is a long-acting amylin receptor agonist — a calcitonin and amylin receptor agent, pharmacologically distinct from the incretin class it is usually discussed alongside ^5,6. A 2026 review positions the whole amylin field explicitly as Beyond GLP-1, framing amylin-based agents as the search for better-tolerated weight-loss drugs ¹¹.

That framing is the substantive claim in this literature. The proposition is not that amylin agonism produces more weight loss than incretin agonism, but that it might produce comparable effect with less gastrointestinal cost. Tolerability, not magnitude, is the hypothesis.

A search limitation to state at the outset. This guide’s search returned only 2026 records. The PubMed timeline shows 9 records in 2021, 6 in 2022, 9 in 2023 and 25 in 2024 — the phase 1 and phase 2 programme that established the compound. None of those were retrieved. Everything below rests on the most recent slice of a literature whose foundations this guide has not read.

02 · Evidence at a glance

Evidence grade

Early Clinical — phase 3 trial evidence located; no marketing authorisation located

What it is

A long-acting amylin receptor agonist, not an incretin agent ^5,11

CagriSema

A fixed-ratio combination of cagrilintide with semaglutide ^6,13

REDEFINE 1

Phase 3a, 68 weeks, adults without diabetes with BMI ≥30, or ≥27 with one obesity-related complication; four arms including cagrilintide alone ¹⁹

The record examined

A secondary, post-hoc analysis of REDEFINE 1 ¹⁹

Weight, versus lifestyle alone

CagriSema −14.8% at one year (95% CI −16.9 to −12.7), moderate to high certainty; tirzepatide −14.9% (−16.0 to −13.9) ⁴

Weight, versus placebo

CagriSema −17.32% (95% CI −19.32 to −15.32); behind retatrutide −22.10% and tirzepatide −19.28% ¹⁴

Head-to-head

Greater weight loss with tirzepatide and CagriSema than semaglutide — but “heterogeneity precluded quantitative synthesis” ¹⁷

GRADE-assessed meta-analysis

Yes, for CagriSema versus placebo, cagrilintide, or semaglutide monotherapy ¹³

Living systematic review

Yes, for the American College of Physicians ⁹

Mechanism, preclinical

Cross-species dorsal vagal complex atlas: over 530,000 cells, 80 neuronal populations, rat, mouse and macaque ²

Receptor interaction work

GLP-1R and calcitonin/amylin receptor co-agonism, additive ¹²; GIPR antagonism sensitises to cagrilintide ¹⁰

Adolescents

Little information available; semaglutide described as the current standard ¹⁸

Cardiovascular outcome trial

None located

Records retrieved

2026 only — the 2021–2024 foundational literature was not retrieved

03 · Mechanism of action

Amylin, not incretin

Cagrilintide agonises the amylin receptor — a receptor complex formed by the calcitonin receptor with receptor activity-modifying proteins, and referred to in the mechanistic literature as CTR/AMYR ¹². Amylin is co-secreted with insulin and acts on satiation through hindbrain circuits. This is a different pathway from GLP-1 receptor agonism, which is why the combination is a combination rather than a dose increase.

The distinction matters editorially. Cagrilintide is repeatedly indexed and discussed alongside GLP-1 drugs because it is sold in a product with one, and because the whole field is described in GLP-1 terms. Pharmacologically it belongs to a separate class, and a guide that lets the marketing category define the pharmacology gets the compound wrong.

Where in the brain, in three species

The strongest mechanistic work located here is a 2026 cross-species atlas of the dorsal vagal complex, built from a transcriptomic dataset of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse and macaque, undertaken specifically to identify the neural mediators of cagrilintide’s effects on energy balance ². An accompanying commentary in the same issue is titled Cellular loci for cagrilintide action identified ¹.

This is unusually good mechanistic work by the standards of this project. Most compounds covered here have a proposed mechanism inferred from a single cell line. This one has a three-species single-cell atlas built to answer the specific question, and a primate is among the three. The qualification is equally clear: it identifies where the drug acts in animals, not what it does to disease outcomes in people.

Why the combination is additive rather than redundant

Co-agonism of the GLP-1 receptor and the calcitonin/amylin receptor in the lateral dorsal tegmental nucleus produced additive effects on homeostatic and motivated feeding ¹² — a mechanistic result consistent with the fixed-ratio product design. Separately, GIP receptor antagonism was found to sensitise to cagrilintide-induced weight loss, with the area postrema responsible for the appetite-suppressing effects of GIP receptor agonism and hypothalamic GIP receptors underlying the opposite manipulation ¹⁰.

The second finding is the more interesting one and cuts against a simple story. In the same paper, GIP receptor agonism and antagonism both affect food intake, through different brain regions. A field that has built a dual GIP/GLP-1 agonist and is now finding that GIP receptor antagonism also promotes weight loss does not yet have a settled account of what GIP does.

04 · Key research findings

Weight, in combination

BMJ network meta-analysis, 2026. Compared with lifestyle modification alone at one year, moderate to high certainty evidence showed substantial weight loss with tirzepatide (mean difference −14.9%, 95% CI −16.0 to −13.9) and with cagrilintide-semaglutide (−14.8%, 95% CI −16.9 to −12.7) ⁴.

The two intervals overlap almost entirely. On this comparison the combination and tirzepatide are not distinguishable, and the certainty rating attached is moderate to high — which is a stronger statement than most numbers in this family carry.

BMJ Medicine network meta-analysis, 2026. Compared with placebo, weight loss was greatest with retatrutide (−22.10%, 95% CI −25.60 to −18.60), followed by tirzepatide (−19.28%, −20.39 to −18.16), then CagriSema (−17.32%, −19.32 to −15.32) ¹⁴.

The synthesis for this system, and it needs stating carefully: these two analyses use different comparators. Against lifestyle alone, CagriSema and tirzepatide are indistinguishable at moderate to high certainty. Against placebo, CagriSema sits third. Neither is wrong; they are answering different questions, and quoting one figure without its comparator would misrepresent both.

GRADE-assessed meta-analysis, 2026. CagriSema evaluated against placebo, cagrilintide alone, or semaglutide alone ¹³.

The only located synthesis whose stated comparators include cagrilintide monotherapy. That makes it the most relevant paper in this guide to the question of what the amylin component contributes, and this guide has read its abstract only.

Amylin-based therapy meta-analysis, 2026. Cagrilintide and CagriSema versus placebo, framed on cagrilintide as a once-weekly amylin receptor agonist and CagriSema as its fixed-dose combination with semaglutide ⁵.

Updated systematic review, 2026. Head-to-head data showed greater weight loss with tirzepatide and CagriSema than with semaglutide. The stated limitation: heterogeneity precluded quantitative synthesis ¹⁷.

That limitation deserves more weight than the finding it accompanies. A systematic review that cannot pool its own data is reporting a direction, not a magnitude.

Living systematic review and network meta-analysis, 2026. Conducted for the American College of Physicians, selecting randomised trials comparing pharmacological weight-management treatments including semaglutide-cagrilintide alongside a dozen others ⁹.

Pipeline reviews, 2026. CagriSema achieved reductions exceeding 20%, alongside tirzepatide and amycretin, with retatrutide exceeding 25% ⁷; a further review lists CagriSema among new dual and triple combinations developed for better efficacy and metabolic outcomes ¹⁶.

The compound alone

REDEFINE 1, secondary post-hoc analysis, 2026. The phase 3a, 68-week trial randomised adults without diabetes with a BMI of at least 30 kg/m², or at least 27 kg/m² with one obesity-related complication, to four once-weekly arms. The regimens used in that protocol were the combination at 2.4 mg/2.4 mg, semaglutide at 2.4 mg, cagrilintide at 2.4 mg, and placebo. The analysis examined anthropometric treatment targets and cardiometabolic outcomes ¹⁹.

Reported as the protocol used in that trial. The design point is what matters here: this is the one located study with a cagrilintide monotherapy arm, and the publication examined is a secondary, post-hoc analysis of it rather than the primary report — which this guide did not retrieve.

Hepatology trial, 2026. A phase 2 dose-ranging randomised trial in fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis included, among its arms, cagrilintide 2.4 mg with semaglutide 2.4 mg ¹⁵.

Included because it is a randomised trial in a hard-endpoint disease area containing a cagrilintide arm. It is a trial of a different compound; cagrilintide appears as a comparator.

Delivery and populations

Dual-chamber pen usability, 2026. A usability study in adults with overweight, obesity or type 2 diabetes, of a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of the fixed-dose combination ³.

This project has repeatedly flagged delivery-engineering literature standing in for efficacy evidence. This is the opposite case and worth naming as such: the pen paper sits alongside phase 3 trials and network meta-analyses, so it reads as what it is — late-stage development of a real product — rather than as a substitute for evidence that does not exist.

Adolescents, 2026. An evidence-based review of current and forthcoming pharmacotherapies for adolescent obesity reports that although no short-term safety issues have been reported, little information is available on tirzepatide and CagriSema in adolescents compared with their known effect in adults, and concludes that semaglutide is the current standard ¹⁸.

Amylin field review, 2026. Advances in peptide engineering, lipidation and reversible albumin binding have enabled long-acting amylin-based agents including cagrilintide, eloralintide, petrelintide and NN1213, differing in pharmacokinetic properties ¹¹; a companion review covers experimental data and early-phase trials across amylin analogues and combination approaches ⁶.

Cardiovascular context, 2026. A state-of-the-art review of incretin analogues as cardiovascular agents summarises evidence across five clinical scenarios ⁸.

Cagrilintide is not the subject of any of those five scenarios. They were defined by the outcome trials that approved agents completed, and this compound has run none located here.

05 · Evidence overview

06 · Safety profile

This section reports the existence and structure of the safety literature. It does not enumerate adverse effects or offer guidance. For a compound without a marketing authorisation there is no product label to defer to.

Animal data. The mechanistic work in rat, mouse and macaque characterises where the compound acts ^2,10,12. No dedicated toxicology study was retrieved in this search, and the pre-2026 literature that would contain it was not returned at all.

Human data. Safety was assessed within REDEFINE 1 ¹⁹ and within the trials pooled by the GRADE-assessed meta-analysis ¹³, the amylin meta-analysis ⁵, the living systematic review ⁹ and the network meta-analyses ^4,14. The adolescent review states that no short-term safety issues have been reported while also stating that little information is available in that population ¹⁸.

Those two statements are compatible and both belong in the same sentence. “No safety issues reported” in a population that has barely been studied is a statement about the volume of observation, not about the compound.

What the tolerability hypothesis implies. The framing of the amylin field as a search for better-tolerated agents ¹¹ is a claim that this class may avoid the gastrointestinal burden that drives discontinuation in the incretin class. This guide located no head-to-head tolerability trial establishing that for cagrilintide, and the reviews that state the hypothesis state it as a research direction.

What is genuinely unknown. Four items.

What cagrilintide does alone. One located trial has a monotherapy arm ¹⁹, read here only through a post-hoc secondary analysis. Everything else measures the combination. The compound’s independent effect size, safety profile and tolerability are, on the evidence retrieved here, substantially uncharacterised.

Cardiovascular and other hard outcomes. No outcome trial was located. The endpoints throughout are weight, anthropometry and cardiometabolic measures ¹⁹.

Anything before 2026. The phase 1 and phase 2 programme was not retrieved. Dose-finding, initial safety and pharmacokinetics all live there.

Anything about non-pharmacy material. No published analysis located here examines the identity, purity or concentration of any cagrilintide-labelled product obtained outside a clinical trial or regulated supply chain.

07 · US regulatory status

Current as of 7 September 2026. This guide located no marketing authorisation for cagrilintide or for the fixed-dose combination in any jurisdiction. The 2026 adolescent review describes semaglutide as the current standard and CagriSema as an agent with little information available in that population ¹⁸, and pipeline reviews list the combination among forthcoming rather than established therapies ^7,16.

This guide has not consulted FDA or EMA records, and the absence of a located approval is not the same as a confirmed absence of approval. This is flagged for primary-source verification.

Cagrilintide is not a controlled substance. An unapproved drug cannot lawfully be supplied for human use in the United States outside an authorised clinical trial or a formal expanded-access pathway.

Under the World Anti-Doping Code, competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The search returned 2026 records only. Roughly 49 records from 2021–2024, including the phase 1 and phase 2 programme, were not retrieved. This is the largest limitation in this guide and it is a limitation of the search, not a finding about the literature.

1. Almost nothing measures the compound alone. One located trial has a cagrilintide monotherapy arm ¹⁹. Every other clinical source reports the fixed-ratio combination, which contains semaglutide — a compound with its own large effect. Attributing combination results to cagrilintide would be a straightforward error and this guide does not make it.

1. The REDEFINE 1 record examined is a secondary, post-hoc analysis ¹⁹, not the primary trial report, which was not retrieved.

1. The two network meta-analyses use different comparators — lifestyle modification alone ⁴ versus placebo ¹⁴ — and produce different rankings. Any single quoted figure is comparator-dependent.

1. The updated systematic review could not pool its data; heterogeneity precluded quantitative synthesis ¹⁷. Its head-to-head conclusion is directional.

1. No cardiovascular or other hard-outcome trial was located. All endpoints retrieved are weight, anthropometric or cardiometabolic measures.

1. The tolerability hypothesis is a hypothesis. The premise that amylin agents are better-tolerated than incretin agents is stated as a research direction in review literature ¹¹, not established here by a head-to-head tolerability trial.

1. The mechanistic work, though strong, is animal work ^2,10,12. A macaque single-cell atlas identifies cellular loci; it does not establish a clinical effect.

1. No dedicated toxicology study was retrieved.

1. The longest trial located ran 68 weeks ¹⁹. Nothing addresses durability beyond that.

1. Sponsor involvement is visible in the REDEFINE 1 analysis and the device usability study through author affiliations ^3,19, as is normal at this stage of development.

1. This guide has read abstracts, not full texts, for every source cited, and one source is indexed without an abstract ¹.

09 · Legal and regulatory appendix

This appendix applies to every compound in this family and is reproduced in each guide.

Approval status. This guide located no marketing authorisation for cagrilintide. Supplying or administering an unapproved drug for human use is unlawful in the United States and in most other jurisdictions outside an authorised trial or expanded-access pathway. This guide does not describe how to obtain the compound and takes no position on any supplier.

Products sold under this name. Material sold as cagrilintide outside a clinical trial has no established relationship to the material used in the studies cited here. This guide located no published analysis of the identity, purity, concentration, sterility or contamination status of any such product. Nothing in the trial evidence described above should be read as applying to it.

Research-use labelling. Material labelled for laboratory research use is not manufactured, tested, or released to the standards applied to medicines intended for people, and such labelling does not make administration lawful or safe.

What this guide is. A description of the published peer-reviewed literature, written for readers who want to understand the state of the evidence. It is not medical advice, not a recommendation, not an endorsement, and not a substitute for a clinician who can assess an individual situation.

Editorial position. Arkham Labs publishes independently and earns through disclosed referral links. That commercial relationship is disclosed on every page carrying such a link and on the editorial standards page. It does not alter what the evidence says, and this guide states plainly that the evidence retrieved here is a recent slice of a literature whose foundations it has not read.

10 · References

1. Hevesi Z, Harkany T. Cellular loci for cagrilintide action identified. Nat Metab. 2026 Jun;8(6):1250–1252. No abstract available.

   PMID 42260118 ↗

2. Ludwig MQ, Coester B, Gordian D, Hassan S, Tomlinson AJ, Toure MH, Christensen OP, Lommi G, Moltke-Prehn A, Brown JM, Belmont-Rausch DM, Bau S, Bodur C, Gowda A, Wu I, Kernodle S, Dong V, Ayensu-Mensah M, Sabatini PV, Shin JH, Kirigiti M, Egerod KL, Le Foll C, Lundh S, Gerstenberg MK, Lutz TA, Kievit P, Secher A, Raun K, Myers MG Jr, Pers TH. A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. Nat Metab. 2026 Jun;8(6):1350–1367.

   PMID 42260119 ↗

3. Gulisano W, Ter-Borch G, Brown P, Feinberg JB, Gonczi M, Hildebrand E, Legere-DeJohn G, Sustarsic R, Sparre T. Ease of use, ease of learning, and convenience of the CagriSema dual-chamber pen: results from a usability study in adults with overweight, obesity, or type 2 diabetes. J Diabetes Sci Technol. 2026 Jun 28:19322968261461530.

   PMID 42366647 ↗

4. Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026 Jul 8;394:e372161.

   PMID 42419792 ↗

5. Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M. Amylin-based obesity therapy: a meta-analysis of cagrilintide and CagriSema versus placebo. Ann Med Surg (Lond). 2026 Jul 13;88(8):5317–5326.

   PMID 42583410 ↗

6. Alhazmi A, le Roux CW. Amylin analogs: the next major class of weight loss therapy: a review of experimental data and early-phase clinical trials. Diabetes Obes Metab. 2026 Jul 14.

   PMID 42452898 ↗

7. Bassatne A, Rizo I. Medical treatments for obesity: what does the future have in store? J Clin Endocrinol Metab. 2026 Jul 14:dgag274.

   PMID 42444567 ↗

8. Araiza-Garaygordobil D, Rico-Fontalvo J, Hernández-Balbuena B, Vinay-Coro M, González-Arias M. Incretin analogues as cardiovascular agents: a state-of-the-art review. Front Endocrinol (Lausanne). 2026 Jul 24;17:1898812. Review.

   PMID 42568490 ↗

9. Damen JAA, Idema DL, Vernooij RWM, Huis In ‘t Veld LF, Kusters MPT, Lokerse ME, de Kanter E, Spijker R, van der Braak K, Jenniskens K, Oerbekke MS, Hooft L. Benefits and harms of pharmacologic treatments in adults with overweight or obesity: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med. 2026 Aug;179(8):1140–1155. Review.

   PMID 42296503 ↗

10. Lewis JE, Montaner M, Nuzzaci D, James-Okoro PP, Harada N, Inagaki N, Dodson WS, Knerr PJ, Douros JD, Gribble FM, Reimann F. Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism. Nat Metab. 2026 Aug;8(8):1669–1678.

    PMID 42498824 ↗

11. Fischer SL, Borner T. Beyond GLP-1: amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. Pharmacol Res. 2026 Aug 12;232:108382. Review.

    PMID 42586227 ↗

12. Sanchez-Navarro MJ, Zhang C, Schmidt HD, Hayes MR. Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding. Physiol Behav. 2026 Aug 15;316:115478.

    PMID 42603595 ↗

13. Khan BW, Agha SA, Qamar I, Khattak MH, Rehman A, Qazi TI, Siddiqui SA, Zeeshan N, Khan UZ, Bibi H, Khan MF, Khan HW, Mian AM, Rafay MA. Maximizing weight loss with CagriSema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2026 Aug 17. Review.

    PMID 42608559 ↗

14. Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, Liu Z, Zha H, Du S, Chen M, Sun W, Guo Q, Cao Y, Li Y. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. BMJ Med. 2026 Aug 27;5(1):e003026.

    PMID 42688617 ↗

15. Loomba R, George J, Castera L, Francque S, Lawitz E, Shoeb A, Clausen JO, Andersen B, Larsen AB, Gluud LL. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol. 2026 Sep;11(9):797–811.

    PMID 42456707 ↗

16. Atal S, Agrawal C, Gupta R, Sadasivam B. Pharmacological management of obesity: current landscape and emerging therapies. Indian J Pharmacol. 2026 Sep 1;58(5):505–512. Review.

    PMID 42683980 ↗

17. Moiz A, Filion KB, Samuels AE, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists and co-agonists for weight loss among adults without diabetes: an updated systematic review. Ann Intern Med. 2026 Sep 1. Review.

    PMID 42673585 ↗

18. Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Dongo-Dueñas LG, Jara-Pianto JMJ, Sierra-Martel JA, Medina-Angulo CA, Virú-Flores HM, Mendoza-Godoy JJ, Zavaleta-Gutiérrez FE, Paz-Ibarra J. Current and forthcoming pharmacotherapies for adolescent obesity: evidence-based review. World J Clin Pediatr. 2026 Sep 9;15(3):118730. Review.

    PMID 42625929 ↗

19. Busetto L, Contreras CO, Christensen MH, Garvey TW, Horn DB, McGowan B, Miller CP, Schnecke V, le Roux CW. Efficacy of CagriSema for reaching anthropometric treatment targets and cardiometabolic outcomes: a secondary, post hoc analysis of REDEFINE 1. Diabetes Obes Metab. 2026 Oct;28(10):9317–9325.

    PMID 42503495 ↗